EMA — authorised 17 September 2018
- Marketing authorisation holder: ALMIRALL SA
- Status: approved
🇪🇺 Sunpg 1622 in European Union
EMA authorised Sunpg 1622 on 17 September 2018
Marketing authorisations
EMA — authorised 17 September 2018
- Application: EMEA/H/C/004514
- Marketing authorisation holder: Almirall, S.A.
- Local brand name: Ilumetri
- Indication: Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
- Status: approved
Sunpg 1622 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Sunpg 1622 approved in European Union?
Yes. EMA authorised it on 17 September 2018; EMA authorised it on 17 September 2018.
Who is the marketing authorisation holder for Sunpg 1622 in European Union?
ALMIRALL SA holds the EU marketing authorisation.